Christina Reschke: MicroRNA Targeting for the Treatment of Epilepsy: the Journey to Preclinical Development

29. 3. 2018, University Campus Bohunice

About the lecture

Epilepsy is a common, serious neurological disease characterized by recurrent seizures. Current anti-epileptic drugs (AEDs) act on a limited set of neuronal targets, are ineffective in a third of patients with epilepsy, and do not show disease-modifying properties.

Evidence has emerged that a class of small, non-coding RNA called microRNA (miRNA) is important in the pathogenesis and potential treatment of epilepsy. MicroRNA-134 is involved in controlling neuronal microstructure and brain excitability and previous studies showed that intracerebroventricular injections of locked nucleic acid (LNA), cholesterol-tagged antagomirs targeting microRNA-134 (Ant-134) reduced evoked and spontaneous seizures in mouse models of status epilepticus.

These protective effects were validated in another rodent specie, and in non-chemical and non-status epilepticus epilepsy models, benefiting translation. Moreover, timed systemic delivery of Ant-134 produced potent and long-lasting disease-modifying effects. These findings suggest efficacious antagomir therapy can be achieved using a clinically-relevant route and provide a rationale for pursuing pre-clinical development of Ant-134 for epilepsy.

Dr. Cristina Reschke

Royal College of Surgeons in Ireland, IE

  • Researcher in Neuroscience focused on mechanisms underlying epilepsy and on the pre-clinical discovery of novel treatments to modify the disease and/or prevent of seizures, brain injuries and related comorbidities.
  • Her specialties are epilepsy in vivo models, experimental video-EEG monitoring, pre-clinical pharmacology, translational research.